NR1H4 and inflammatory bowel disease: Previous studies have also shown that deletion of unbound and secondary BAs leads to activation of the farnesol X receptor (FXR), which may impair anti-inflammatory pathways and intestinal barrier function, ultimately contributing to the pathogenesis of inflammatory bowel disease [11,63].